Clinical Trial Update: Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/Phase 2 study of Tecemotide (L-BLP25) in participants with stage III unresectable non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tecemotide (L-BLP25) (tecemotide)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-10-21